Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Budget good for large corporates and academia, but little for biotechs

This article was originally published in Scrip

Executive Summary

The UK Chancellor of the Exchequer [finance minister] George Osborne assured Parliament on 21 March that he would be backing industries such as pharmaceuticals, amongst others, in an effort to reduce the dominance of the financial services industry.

You may also be interested in...



1-2-300! The biosimilar horde stands at the gate

Despite claims from 'research-based' biologics manufacturers and their representatives in the EU and US that the biosimilars market is small and relatively unimportant, the age of biosimilars is clearly already upon us. A recently launched database from Datamonitor reveals a total of 556 biosimilars currently in development or being marketed globally with over 200 companies involved in the endeavour.

Biosimilars regulation in emerging markets

Mark Hollis explores developments in emerging markets and considers what their impact might be on growth.

Pharma faces $2 billion cut in drugs bill as Greece debt crisis deepens

Pharmaceutical companies are likely to be reeling today with the announcement that €2.1 billion ($2.8 billion) of healthcare spending cuts will take place during 2011–15 in Greece. These cuts will be implemented through widening the use of electronic prescribing, and drug price cuts. This will not only negatively impact pharmaceutical company sales in Greece, but also sales in other countries which reference Greek drug prices.

UsernamePublicRestriction

Register

SC016700

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel